140 related articles for article (PubMed ID: 22790141)
1. Resolution of cranial MRI and SPECT abnormalities in a patient with Wilson's disease following oral zinc monotherapy.
Ishida S; Doi Y; Yamane K; Sugino M; Kimura F; Hanafusa T; Fukui H; Tamai H
Intern Med; 2012; 51(13):1759-63. PubMed ID: 22790141
[TBL] [Abstract][Full Text] [Related]
2. Wilson's disease: resolution of MRI lesions following long-term oral zinc therapy.
Huang CC; Chu NS
Acta Neurol Scand; 1996; 93(2-3):215-8. PubMed ID: 8741147
[TBL] [Abstract][Full Text] [Related]
3. [Short interval change of 99mTc-ethyl cysteinate dimer single photon emission computed tomography in Wilson's disease].
Imai N; Nozaki H; Miyata K; Terayama Y; Ishihara N
No To Shinkei; 1999 Sep; 51(9):785-9. PubMed ID: 10511956
[TBL] [Abstract][Full Text] [Related]
4. Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.
Leggio L; Ferrulli A; Mirijello A; Abenavoli L; Di Giuda D; Funiciello S; Rotoli M; Gasbarrini G; Addolorato G
Int J Immunopathol Pharmacol; 2007; 20(1):185-90. PubMed ID: 17346443
[TBL] [Abstract][Full Text] [Related]
5. Morphological and functional imaging in neurological and non-neurological Wilson's patients.
Hermann W
Ann N Y Acad Sci; 2014 May; 1315():24-9. PubMed ID: 24495036
[TBL] [Abstract][Full Text] [Related]
6. [Magnetic Resonance Imaging Improvement in a Patient with Wilson's Disease Following Treatment with Trientine Hydrochloride and Zinc Acetate].
Kim Y; Koide R; Kawata A
Brain Nerve; 2015 May; 67(5):635-8. PubMed ID: 25957210
[TBL] [Abstract][Full Text] [Related]
7. Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease.
Schwarz J; Antonini A; Kraft E; Tatsch K; Vogl T; Kirsch CM; Leenders KL; Oertel WH
Neurology; 1994 Jun; 44(6):1079-82. PubMed ID: 8208404
[TBL] [Abstract][Full Text] [Related]
8. Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease.
Huang CC; Chu NS
Eur Neurol; 1998; 39(1):32-7. PubMed ID: 9476721
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of regional cerebral blood flow and distribution volume in Machado-Joseph disease by iodine-123I IMP single photon emission computed tomography].
Hayashi T; Nakajima T; Fukuhara N
Rinsho Shinkeigaku; 2001 Sep; 41(9):574-81. PubMed ID: 11968740
[TBL] [Abstract][Full Text] [Related]
10. [Cerebral magnetic resonance in Wilson's disease].
Amato C; Bisceglie P; Moschini M
Radiol Med; 1994 Dec; 88(6):752-7. PubMed ID: 7878232
[TBL] [Abstract][Full Text] [Related]
11. A study of brain MRI characteristics and clinical features in 76 cases of Wilson's disease.
Zhong W; Huang Z; Tang X
J Clin Neurosci; 2019 Jan; 59():167-174. PubMed ID: 30385165
[TBL] [Abstract][Full Text] [Related]
12. Six-year clinical and MRI quantitative susceptibility mapping (QSM) follow-up in neurological Wilson's disease under zinc therapy: a case report.
Zaino D; Chiarotti I; Battisti C; Salvatore S; Federico A; Cerase A
Neurol Sci; 2019 Jan; 40(1):199-201. PubMed ID: 30209700
[No Abstract] [Full Text] [Related]
13. Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease.
Piga M; Murru A; Satta L; Serra A; Sias A; Loi G; Marrosu F; Demelia L
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):716-24. PubMed ID: 18180918
[TBL] [Abstract][Full Text] [Related]
14. Effect of D-penicillamine treatment on brain metabolism in Wilson's disease: a case study.
De Volder A; Sindic CJ; Goffinet AM
J Neurol Neurosurg Psychiatry; 1988 Jul; 51(7):947-9. PubMed ID: 3264567
[TBL] [Abstract][Full Text] [Related]
15. Regional morphometric abnormalities and clinical relevance in Wilson's disease.
Zou L; Song Y; Zhou X; Chu J; Tang X
Mov Disord; 2019 Apr; 34(4):545-554. PubMed ID: 30817852
[TBL] [Abstract][Full Text] [Related]
16. Wilson's disease. Development of neurological disease after beginning penicillamine therapy.
Glass JD; Reich SG; DeLong MR
Arch Neurol; 1990 May; 47(5):595-6. PubMed ID: 2334309
[TBL] [Abstract][Full Text] [Related]
17. Wilson's disease: two treatment modalities. Correlations to pretreatment and posttreatment brain MRI.
da Costa Mdo D; Spitz M; Bacheschi LA; Leite CC; Lucato LT; Barbosa ER
Neuroradiology; 2009 Oct; 51(10):627-33. PubMed ID: 19479249
[TBL] [Abstract][Full Text] [Related]
18. Clinical and neuroradiological improvement in chronic acquired hepatocerebral degeneration after branched-chain amino acid therapy.
Ueki Y; Isozaki E; Miyazaki Y; Koide R; Shimizu T; Yagi K; Hirai S
Acta Neurol Scand; 2002 Aug; 106(2):113-6. PubMed ID: 12100372
[TBL] [Abstract][Full Text] [Related]
19. Zinc acetate treatment in Wilson's disease.
Anderson LA; Hakojarvi SL; Boudreaux SK
Ann Pharmacother; 1998 Jan; 32(1):78-87. PubMed ID: 9475826
[TBL] [Abstract][Full Text] [Related]
20. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
